BOUNDLESS BIO, INC. Stock-Based Compensation
BOUNDLESS BIO, INC. (BOLD) reported Stock-Based Compensation of $4.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-07
- BOUNDLESS BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.22M, a 90.31% increase year-over-year.
- BOUNDLESS BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.37M, a 23.71% decline year-over-year.
- BOUNDLESS BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.33M, a 33.67% decline year-over-year.
- BOUNDLESS BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.30M, a 36.28% decline year-over-year.
- BOUNDLESS BIO, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $6.13M, a 18.51% decline from fiscal 2024.
- BOUNDLESS BIO, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $7.52M, a 125.30% increase from fiscal 2023.
- BOUNDLESS BIO, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $3.34M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $4.59M 10-Q · filed 2026-08-07 | $5.92M derived: sum of 3 quarters · filed 2026-08-07 | $7.23M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $1.37M 10-Q · filed 2026-05-08 | $2.70M derived: sum of 2 quarters · filed 2026-05-08 | $4.01M derived: sum of 3 quarters · filed 2026-05-08 | $5.70M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.63M derived: sum of 2 quarters · filed 2026-03-09 | $4.33M derived: sum of 3 quarters · filed 2026-08-07 | $6.13M 10-K · filed 2026-03-09 |
| 2025-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.00M derived: sum of 2 quarters · filed 2026-08-07 | $4.79M 10-Q · filed 2025-11-05 | $6.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $1.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $3.49M 10-Q · filed 2026-08-07 | $5.50M derived: sum of 3 quarters · filed 2026-08-07 | $7.54M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $1.80M 10-Q · filed 2026-05-08 | $3.81M derived: sum of 2 quarters · filed 2026-05-08 | $5.85M derived: sum of 3 quarters · filed 2026-05-08 | $7.99M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $4.05M derived: sum of 2 quarters · filed 2026-03-09 | $6.19M derived: sum of 3 quarters · filed 2026-03-09 | $7.52M 10-K · filed 2026-03-09 |
| 2024-09-30 | $2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.18M derived: sum of 2 quarters · filed 2025-11-05 | $5.51M 10-Q · filed 2025-11-05 | $6.42M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $3.46M 10-Q · filed 2025-08-05 | $4.37M derived: sum of 3 quarters · filed 2025-08-05 | $5.26M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $1.33M 10-Q · filed 2025-05-09 | $2.24M derived: sum of 2 quarters · filed 2025-05-09 | $3.12M derived: sum of 3 quarters · filed 2025-05-09 | $4.05M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $911.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.79M derived: sum of 2 quarters · filed 2025-03-27 | $2.72M derived: sum of 3 quarters · filed 2025-03-27 | $3.34M 10-K · filed 2025-03-27 |
| 2023-09-30 | $883.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.81M derived: sum of 2 quarters · filed 2024-11-07 | $2.42M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $927.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.54M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $615.00K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |